These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 28673027)
1. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children. Kityo C; Boerma RS; Sigaloff KCE; Kaudha E; Calis JCJ; Musiime V; Balinda S; Nakanjako R; Boender TS; Mugyenyi PN; Rinke de Wit TF J Antimicrob Chemother; 2017 Sep; 72(9):2587-2595. PubMed ID: 28673027 [TBL] [Abstract][Full Text] [Related]
2. Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children. Huibers MHW; Kityo C; Boerma RS; Kaudha E; Sigaloff KCE; Balinda SN; Bertagnolio S; Nakanjako R; Mugyenyi P; Calis JCJ; Boele van Hensbroek M; Rinke de Wit TF J Antimicrob Chemother; 2019 Oct; 74(10):3035-3043. PubMed ID: 31289811 [TBL] [Abstract][Full Text] [Related]
3. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project. Ngo-Giang-Huong N; Wittkop L; Judd A; Reiss P; Goetghebuer T; Duiculescu D; Noguera-Julian A; Marczynska M; Giacquinto C; Ene L; Ramos JT; Cellerai C; Klimkait T; Brichard B; Valerius N; Sabin C; Teira R; Obel N; Stephan C; de Wit S; Thorne C; Gibb D; Schwimmer C; Campbell MA; Pillay D; Lallemant M; BMC Infect Dis; 2016 Nov; 16(1):654. PubMed ID: 27825316 [TBL] [Abstract][Full Text] [Related]
4. High prevalence of virological failure and HIV drug mutations in a first-line cohort of Malawian children. Huibers MHW; Moons P; Cornelissen M; Zorgdrager F; Maseko N; Gushu MB; Iwajomo OH; Boele van Hensbroek M; Calis JCJ J Antimicrob Chemother; 2018 Dec; 73(12):3471-3475. PubMed ID: 30169653 [TBL] [Abstract][Full Text] [Related]
5. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546 [TBL] [Abstract][Full Text] [Related]
6. Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-naïve Ugandan children. Soeria-Atmadja S; Amuge P; Nanzigu S; Bbuye D; Rubin J; Eriksen J; Kekitiinwa A; Obua C; Gustafsson LL; Navér L Acta Paediatr; 2020 Dec; 109(12):2706-2716. PubMed ID: 32304595 [TBL] [Abstract][Full Text] [Related]
7. Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda. Omooja J; Nannyonjo M; Sanyu G; Nabirye SE; Nassolo F; Lunkuse S; Kapaata A; Segujja F; Kateete DP; Ssebaggala E; Bbosa N; Aling E; Nsubuga RN; Kaleebu P; Ssemwanga D J Antimicrob Chemother; 2019 Oct; 74(10):3021-3029. PubMed ID: 31257432 [TBL] [Abstract][Full Text] [Related]
8. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial. Szubert AJ; Prendergast AJ; Spyer MJ; Musiime V; Musoke P; Bwakura-Dangarembizi M; Nahirya-Ntege P; Thomason MJ; Ndashimye E; Nkanya I; Senfuma O; Mudenge B; Klein N; Gibb DM; Walker AS; PLoS Med; 2017 Nov; 14(11):e1002432. PubMed ID: 29136032 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial. Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716 [TBL] [Abstract][Full Text] [Related]
10. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children. Boerma RS; Boender TS; Sigaloff KC; Rinke de Wit TF; van Hensbroek MB; Ndembi N; Adeyemo T; Temiye EO; Osibogun A; Ondoa P; Calis JC; Akanmu AS J Int AIDS Soc; 2016; 19(1):21140. PubMed ID: 27836020 [TBL] [Abstract][Full Text] [Related]
11. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R; Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603 [TBL] [Abstract][Full Text] [Related]
12. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults. Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P; BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730 [TBL] [Abstract][Full Text] [Related]
13. Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals. Chimukangara B; Giandhari J; Lessells R; Yende-Zuma N; Sartorius B; Samuel R; Khanyile KS; Stray-Pedersen B; Moodley P; Metzner KJ; Padayatchi N; Naidoo K; De Oliveira T J Antimicrob Chemother; 2020 Nov; 75(11):3319-3326. PubMed ID: 32772079 [TBL] [Abstract][Full Text] [Related]
14. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391 [TBL] [Abstract][Full Text] [Related]
15. Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. Bachmann N; von Braun A; Labhardt ND; Kadelka C; Günthard HF; Sekaggya-Wiltshire C; Castelnuovo B; Kambugu A; Lejone TI; Böni J; Yerly S; Perreau M; Klimkait T; Kouyos RD; Fehr J; J Antimicrob Chemother; 2019 Feb; 74(2):468-472. PubMed ID: 30476115 [TBL] [Abstract][Full Text] [Related]
16. High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo. Salou M; Dagnra AY; Butel C; Vidal N; Serrano L; Takassi E; Konou AA; Houndenou S; Dapam N; Singo-Tokofaï A; Pitche P; Atakouma Y; Prince-David M; Delaporte E; Peeters M J Int AIDS Soc; 2016; 19(1):20683. PubMed ID: 27125320 [TBL] [Abstract][Full Text] [Related]
17. HIV-1 pretreatment drug resistance in vertically infected children is associated with poor virological response to protease inhibitor (PI)-based first-line antiretroviral therapy (ART): results from a cohort study in Argentina. Rozenszajn M; Arazi-Caillaud S; Taicz M; Bologna R; Mangano A; Aulicino PC J Antimicrob Chemother; 2022 Jun; 77(7):1969-1973. PubMed ID: 35512329 [TBL] [Abstract][Full Text] [Related]
18. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016. Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167 [TBL] [Abstract][Full Text] [Related]
19. Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia. Hudson FP; Mulenga L; Westfall AO; Warrier R; Mweemba A; Saag MS; Stringer JS; Eron JJ; Chi BH Antivir Ther; 2019; 24(4):291-300. PubMed ID: 30977467 [TBL] [Abstract][Full Text] [Related]
20. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]